Ignite Creation Date:
2024-05-06 @ 4:03 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04855760
Status:
COMPLETED
Last Update Posted:
2023-11-03
First Post:
2021-04-19
Brief Title:
Safety of REL-1017 for Major Depressive Disorder
Sponsor:
Relmada Therapeutics Inc
Organization:
Relmada Therapeutics Inc
Study Overview
Official Title:
A Phase 3 Multicenter Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT06009003
Has Expanded Access, NCT# Status:
AVAILABLE
Acronym:
RELIANCE-OLS
Brief Summary:
This was a 1-year multicenter open-label long-term study to assess the safety of REL-1017 once daily QD as monotherapy or as adjunctive treatment of Major Depressive Disorder Adjunctive study participants continued to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period
Detailed Description:
This was a multicenter open-label long-term study of REL-1017 to evaluate the long-term safety and long-term durability of response in patients with MDD Patients who completed previous randomized double-blind Phase 3 trials NCT04688164 NCT04855747 NCT05081167 of REL-1017 as adjunctive therapy or monotherapy for MDD were asked to continue treatment with REL-1017 25 mg daily for up to 1 year De novo patients who satisfied inclusionexclusion criteria also were enrolled and received a 75 mg loading dose of REL-1017 on Day 1 followed by a maintenance dose of 25 mg REL-1017 daily for the remainder of the study Days 2-365 When REL-1017 was administered as adjunctive treatment patients continued to use a stable dosage of their concomitant antidepressants
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None